Drug Profile
LYS 006
Alternative Names: LYS-006Latest Information Update: 22 Jun 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Amines; Anti-inflammatories; Antiacnes; Butyric acids; Halogenated hydrocarbons; Hepatoprotectants; Phenyl ethers; Pyridines; Skin disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Leukotriene A4 hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acne; Hidradenitis suppurativa; Non-alcoholic steatohepatitis; Ulcerative colitis
Most Recent Events
- 07 Jun 2023 Novartis Pharmaceuticals terminates phase II trial in Czech Republic, US, Germany, Hungary, Norway, Poland, Russia, Slovakia and Bulgaria, due to sponsor decision due to strategic considerations (PO) (NCT04074590)
- 09 Mar 2022 Novartis completes a phase-II clinical trials in Acne in Czech Republic, Hungary, Germany, Netherlands, France and USA (PO) (NCT03497897) (EudraCT2017-003191-30)
- 05 Jan 2022 Novartis terminates the phase II NEXSCOT trial in Non-alcoholic steatohepatitis (Monotherapy, Combination therapy) in Argentina, USA, Germany (PO) (NCT04147195)